Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Active not recruiting 3Terminated 2Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 18Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Glioblastoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Glioma 1Blast Crisis 1Amyloidosis 1

Interventions

Dexamethasone 2venetoclax 1selinexor 1ethanolamine oleate 1daratumumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Psychiatric Rehabilitation 1Pentetic Acid 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Ethanol 1Edetic Acid 1Drug Therapy 1Calcium Dobesilate 1Biological Assay 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Immunoglobulin Light-chain Amyloidosis × Calcium Dobesilate × Clear all
NCT05486481 2025-03-06

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

University of California, San Francisco

Phase 1/2 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡